Form 425 - Prospectuses and communications, business combinations:
SEC Accession No. 0001437749-18-001427
Filing Date
2018-02-01
Accepted
2018-02-01 06:19:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 FORM 425 avir20180130_425.htm 425 20812
2 vaxartlogo1.jpg GRAPHIC 8670
  Complete submission text file 0001437749-18-001427.txt   35077
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filed by) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 425
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Subject) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 425 | Act: 34 | File No.: 001-35285 | Film No.: 18564592
SIC: 2836 Biological Products, (No Diagnostic Substances)